Tiziana Life Sciences Nasal Therapy Boosts Brain Health
Boston, MA, USA – April 1, 2026 In a promising development for age-related cognitive decline and neurodegenerative disorders, Tiziana...
Neurodegeneration
Advertisement
FDA Clears First-in-Class Vectorized Antibody ALS Trial With VTx-002
Amsterdam, The Netherlands, and Boston, MA — January 8, 2026 — VectorY Therapeutics announced that the U.S. Food and...
AC Immune’s Phase 2 Data Shows Promise in Slowing Parkinson’s Progression
LAUSANNE, Switzerland — December 11, 2025 — AC Immune SA has released positive interim Phase 2 data for its...
China Adds LEQEMBI to Insurance List for Early Alzheimer’s
TOKYO and CAMBRIDGE, Mass., December 8, 2025 — Eisai Co., Ltd. and Biogen Inc. announced that LEQEMBI® (lecanemab), an...
Zervimesine Phase 3 Plan Advances Alzheimer’s Drug Strategy
Purchase, N.Y. — December 1, 2025 — Cognition Therapeutics has unveiled its Phase 3 registrational plan for Zervimesine (CT1812)...
Advertisements
Elanco Leader Joins Neurizon to Boost ALS Drug Program
MELBOURNE, Australia – Nov. 26, 2025 — Neurizon Therapeutics (ASX: NUZ & NUZOA; OTCQB: NUZTF), a clinical-stage biotech firm...
Aspen Neuroscience Secures $115M to Advance Cell Therapy
SAN DIEGO, CA — November 20, 2025 — Aspen Neuroscience, a leading developer of personalized autologous cell therapies for...
FDA Clears Jupiter Neurosciences’ JOTROL™ for Phase 2a Parkinson’s Trial
JUPITER, Florida, November 5, 2025 — Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage biopharmaceutical company, announced that the U.S....
FDA Grants Orphan Drug Status to Cellenkos’ CK0803 for ALS Treatment
HOUSTON, Oct. 20, 2025 – The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to...
Coya’s COYA 303 Shows Promise in Neuroinflammation and Treg Boost
HOUSTON, Sept. 16, 2025 – Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company specializing in regulatory T cell...
Advertisement
